<!DOCTYPE html>
<html lang="en-us"
  dir="ltr">

<head>
  <meta charset="utf-8">
<meta name="viewport" content="width=device-width">



<link rel="icon" type="image/ico" href="https://reports.muthu.co/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://reports.muthu.co/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://reports.muthu.co/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="192x192" href="https://reports.muthu.co/android-chrome-192x192.png">
<link rel="apple-touch-icon" sizes="180x180" href="https://reports.muthu.co/apple-touch-icon.png">

<meta name="description" content=""/>



<title>
    
    Suven Pharmaceuticals Ltd:Annual Report 2023-24 Analysis | Financial Report Insights
    
</title>
<link href="/_pagefind/pagefind-ui.css" rel="stylesheet">
<script src="/_pagefind/pagefind-ui.js"></script>
<link rel="canonical" href="https://reports.muthu.co/posts/suven-pharmaceuticals-ltdannual-report-2023-24-analysis/"/>

<meta property="og:url" content="https://reports.muthu.co/posts/suven-pharmaceuticals-ltdannual-report-2023-24-analysis/">
  <meta property="og:site_name" content="Financial Report Insights">
  <meta property="og:title" content="Suven Pharmaceuticals Ltd:Annual Report 2023-24 Analysis">
  <meta property="og:description" content="Suven Pharmaceuticals Ltd: A Comprehensive Overview # About the Company # Year of Establishment and Founding History: Suven Pharmaceuticals Ltd. was established in 2003 as a spin-off from Suven Life Sciences Limited.
Headquarters Location and Global Presence: The company is headquartered in Hyderabad, India. They operate globally, with a strong presence in North America, Europe, and Asia.
Company Vision and Mission: While a specific publicly declared vision and mission statement are not readily available, Suven Pharmaceuticals focuses on being a premier contract development and manufacturing organization (CDMO) and API supplier, providing high-quality and cost-effective solutions to global pharmaceutical companies.">
  <meta property="og:locale" content="en_us">
  <meta property="og:type" content="article">
    <meta property="article:section" content="posts">
    <meta property="article:published_time" content="2024-07-16T21:18:07+00:00">
    <meta property="article:modified_time" content="2024-07-16T21:18:07+00:00">
    <meta property="article:tag" content="Suven Pharmaceuticals Ltd.">
    <meta property="article:tag" content="SUVENPHAR">
    <meta property="article:tag" content="Pharmaceuticals - Diversified">
    <meta property="article:tag" content="Healthcare">
    <meta property="article:tag" content="Mid Cap">
    <meta property="article:tag" content="Annual Report">













<link rel="stylesheet" href="/assets/combined.min.83aead7461ea8e7fcfbb79b8c9400e1ec33efe08796484ba7a94d30f7b4923a8.css" media="all">




      <script async src="https://www.googletagmanager.com/gtag/js?id=G-T7PH4WNH24"></script>
      <script>
        var doNotTrack = false;
        if ( false ) {
          var dnt = (navigator.doNotTrack || window.doNotTrack || navigator.msDoNotTrack);
          var doNotTrack = (dnt == "1" || dnt == "yes");
        }
        if (!doNotTrack) {
          window.dataLayer = window.dataLayer || [];
          function gtag(){dataLayer.push(arguments);}
          gtag('js', new Date());
          gtag('config', 'G-T7PH4WNH24');
        }
      </script>




<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-3609399560636561" crossorigin="anonymous"></script>
</head>







<body class="light">
  <div class="content">
    <header>
      

<div class="header">

    
    <div id="search"></div>
</div>

    </header>
    <main class="main">
      





<div class="breadcrumbs">
    
    <a href="/">Home</a>
    <span class="breadcrumbs-separator"> > </span>
    
    <a href="/posts/">Posts</a>
    <span class="breadcrumbs-separator"> > </span>
    
    <a class="breadcrumbs-current" href="/posts/suven-pharmaceuticals-ltdannual-report-2023-24-analysis/">Suven Pharmaceuticals Ltd:Annual Report 2023-24 Analysis</a>
</div>



<div >

  <div class="single-intro-container">

    

    <h1 class="single-title" data-pagefind-body>Suven Pharmaceuticals Ltd:Annual Report 2023-24 Analysis</h1>
    

    

    <p class="single-readtime">
      
      
      
      <time datetime="2024-07-16T21:18:07&#43;00:00">July 16, 2024</time>
      

      
      &nbsp; · &nbsp;
      20 min read
      
    </p>

  </div>

  

  
  

  <div class="single-tags">
    
    <span>
      <a href="https://reports.muthu.co/tags/suven-pharmaceuticals-ltd./">#Suven Pharmaceuticals Ltd.</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/suvenphar/">#SUVENPHAR</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/pharmaceuticals---diversified/">#Pharmaceuticals - Diversified</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/healthcare/">#Healthcare</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/mid-cap/">#Mid Cap</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/annual-report/">#Annual Report</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/2023-24/">#2023-24</a>
    </span>
    
    
  </div>

  
  

  

  
  <aside class="toc">
    <p><strong>Table of contents</strong></p>
    <nav id="TableOfContents">
  <ul>
    <li><a href="#suven-pharmaceuticals-ltd-a-comprehensive-overview">Suven Pharmaceuticals Ltd: A Comprehensive Overview</a>
      <ul>
        <li><a href="#about-the-company">About the Company</a></li>
        <li><a href="#their-products">Their Products</a></li>
        <li><a href="#primary-customers">Primary Customers</a></li>
        <li><a href="#major-competitors">Major Competitors</a></li>
        <li><a href="#future-outlook">Future Outlook</a></li>
      </ul>
    </li>
    <li><a href="#suven-pharmaceuticals-limited-financial-analysis">Suven Pharmaceuticals Limited: Financial Analysis</a>
      <ul>
        <li><a href="#3-year-trend-analysis-of-key-financial-metrics">3-Year Trend Analysis of Key Financial Metrics</a></li>
        <li><a href="#business-segment-performance">Business Segment Performance</a></li>
        <li><a href="#major-strategic-initiatives-and-their-progress">Major Strategic Initiatives and Their Progress</a></li>
        <li><a href="#risk-landscape-changes">Risk Landscape Changes</a></li>
        <li><a href="#esg-initiatives-and-metrics">ESG Initiatives and Metrics</a></li>
        <li><a href="#management-outlook">Management Outlook</a></li>
      </ul>
    </li>
    <li><a href="#financial-position-analysis-of-suven-pharmaceuticals-limited">Financial Position Analysis of Suven Pharmaceuticals Limited</a>
      <ul>
        <li><a href="#balance-sheet---3-year-comparative-analysis-consolidated-in-c-lakhs">Balance Sheet - 3-Year Comparative Analysis (Consolidated, in C Lakhs)</a></li>
        <li><a href="#significant-year-over-year-changes-10">Significant Year-over-Year Changes (&gt;10%)</a></li>
        <li><a href="#working-capital-trends">Working Capital Trends</a></li>
        <li><a href="#debt-structure-and-maturity-profile">Debt Structure and Maturity Profile</a></li>
        <li><a href="#off-balance-sheet-items">Off-Balance Sheet Items</a></li>
      </ul>
    </li>
    <li><a href="#operating-performance-analysis-of-suven-pharmaceuticals-fy24">Operating Performance Analysis of Suven Pharmaceuticals (FY24)</a>
      <ul>
        <li><a href="#revenue-breakdown">Revenue Breakdown</a></li>
        <li><a href="#cost-structure-analysis-standalone">Cost Structure Analysis (Standalone)</a></li>
        <li><a href="#margin-analysis-consolidated">Margin Analysis (Consolidated)</a></li>
        <li><a href="#non-recurring-items-consolidated">Non-Recurring Items (Consolidated)</a></li>
        <li><a href="#gaap-vs-non-gaap-reconciliation">GAAP vs. Non-GAAP Reconciliation</a></li>
        <li><a href="#eps-analysis-consolidated">EPS Analysis (Consolidated)</a></li>
      </ul>
    </li>
    <li><a href="#cash-management-suven-pharmaceuticals-financial-analysis">Cash Management: Suven Pharmaceuticals Financial Analysis</a>
      <ul>
        <li><a href="#cash-flow-and-liquidity-analysis">Cash Flow and Liquidity Analysis</a></li>
      </ul>
    </li>
    <li><a href="#financial-analysis-key-performance-indicators">Financial Analysis: Key Performance Indicators</a>
      <ul>
        <li><a href="#profitability-ratios-3-year-trends">Profitability Ratios (3-Year Trends)</a></li>
        <li><a href="#liquidity-metrics">Liquidity Metrics</a></li>
        <li><a href="#efficiency-ratios">Efficiency Ratios</a></li>
        <li><a href="#leverage-metrics">Leverage Metrics</a></li>
        <li><a href="#working-capital-ratios">Working Capital Ratios</a></li>
        <li><a href="#comparison-with-industry-averages-and-significant-deviations">Comparison with Industry Averages and Significant Deviations</a></li>
      </ul>
    </li>
    <li><a href="#suven-pharmaceuticals-limited-financial-analysis-fy24">Suven Pharmaceuticals Limited: Financial Analysis (FY24)</a>
      <ul>
        <li><a href="#segment-performance-analysis">Segment Performance Analysis</a></li>
      </ul>
    </li>
    <li><a href="#suven-pharmaceuticals-limited---segment-wise-risk-analysis-fy2023-24-vs-fy2022-23">Suven Pharmaceuticals Limited - Segment-Wise Risk Analysis (FY2023-24 vs. FY2022-23)</a></li>
    <li><a href="#strategic-risks">Strategic Risks</a></li>
    <li><a href="#operational-risks">Operational Risks</a></li>
    <li><a href="#financial-risks">Financial Risks</a></li>
    <li><a href="#complianceregulatory-risks">Compliance/Regulatory Risks</a></li>
    <li><a href="#emerging-risks">Emerging Risks</a>
      <ul>
        <li><a href="#geopolitical-risks">Geopolitical Risks</a></li>
        <li><a href="#agrochemical-sector-risks">Agrochemical Sector Risks</a></li>
      </ul>
    </li>
    <li><a href="#strategic-and-management-analysis-of-suven-pharmaceuticals">Strategic and Management Analysis of Suven Pharmaceuticals</a>
      <ul>
        <li><a href="#long-term-strategic-goals-and-progress">Long-Term Strategic Goals and Progress</a></li>
        <li><a href="#competitive-advantages-and-market-positioning">Competitive Advantages and Market Positioning</a></li>
        <li><a href="#innovation-initiatives-and-rd-effectiveness">Innovation Initiatives and R&amp;D Effectiveness</a></li>
        <li><a href="#ma-strategy-and-execution">M&amp;A Strategy and Execution</a></li>
        <li><a href="#managements-track-record-in-execution">Management&rsquo;s Track Record in Execution</a></li>
        <li><a href="#capital-allocation-strategy">Capital Allocation Strategy</a></li>
        <li><a href="#organizational-changes-and-their-impact">Organizational Changes and Their Impact</a></li>
      </ul>
    </li>
    <li><a href="#esg-framework">ESG Framework</a>
      <ul>
        <li><a href="#environmental-metrics-and-targets">Environmental Metrics and Targets</a></li>
        <li><a href="#social-responsibility-programs">Social Responsibility Programs</a></li>
        <li><a href="#governance-structure-and-effectiveness">Governance Structure and Effectiveness</a></li>
        <li><a href="#regulatory-compliance-and-future-preparations">Regulatory Compliance and Future Preparations</a></li>
      </ul>
    </li>
  </ul>
</nav>
  </aside>
  

  

  <div class="single-content">
    <h2 class="heading" id="suven-pharmaceuticals-ltd-a-comprehensive-overview">
  Suven Pharmaceuticals Ltd: A Comprehensive Overview
  <a class="anchor" href="#suven-pharmaceuticals-ltd-a-comprehensive-overview">#</a>
</h2>
<h3 class="heading" id="about-the-company">
  About the Company
  <a class="anchor" href="#about-the-company">#</a>
</h3>
<p><strong>Year of Establishment and Founding History:</strong> Suven Pharmaceuticals Ltd. was established in 2003 as a spin-off from Suven Life Sciences Limited.</p>
<p><strong>Headquarters Location and Global Presence:</strong> The company is headquartered in Hyderabad, India. They operate globally, with a strong presence in North America, Europe, and Asia.</p>
<p><strong>Company Vision and Mission:</strong> While a specific publicly declared vision and mission statement are not readily available, Suven Pharmaceuticals focuses on being a premier contract development and manufacturing organization (CDMO) and API supplier, providing high-quality and cost-effective solutions to global pharmaceutical companies.</p>
<p><strong>Key Milestones in their Growth Journey:</strong></p>
<ul>
<li><strong>2003:</strong> Spin-off from Suven Life Sciences Limited.</li>
<li><strong>Expansion of CDMO capabilities:</strong> Significant investments in expanding manufacturing infrastructure and R&amp;D capabilities.</li>
<li><strong>Strategic Acquisitions:</strong> Acquisition of Casper Pharma further solidifying presence in the CDMO space.</li>
</ul>
<p><strong>Stock Exchange Listing Details and Market Capitalization:</strong> Suven Pharmaceuticals is listed on the Bombay Stock Exchange (BSE: 543064) and the National Stock Exchange (NSE: SUVENPHAR). The market capitalization fluctuates with market conditions; please refer to financial websites for the most up-to-date information.</p>
<p><strong>Recent Financial Performance Highlights:</strong> (Please refer to the company&rsquo;s official financial reports and investor presentations for the most current data.)</p>
<p><strong>Management Team and Leadership Structure:</strong> The company is led by a team of experienced professionals in the pharmaceutical industry. Key leadership typically includes:</p>
<ul>
<li><strong>Managing Director/CEO:</strong> Driving overall strategy and operations.</li>
<li><strong>Chief Financial Officer (CFO):</strong> Overseeing financial management.</li>
<li><strong>Chief Operating Officer (COO):</strong> Managing day-to-day operations.</li>
</ul>
<p><strong>Any Notable Awards or Recognitions:</strong> Suven Pharmaceuticals has received awards and recognition for its quality, safety, and sustainability practices. (Please refer to the company&rsquo;s website or press releases for details.)</p>
<h3 class="heading" id="their-products">
  Their Products
  <a class="anchor" href="#their-products">#</a>
</h3>
<p><strong>Complete Product Portfolio with Categories:</strong> Suven Pharmaceuticals operates primarily in two segments:</p>
<ul>
<li><strong>Contract Development and Manufacturing Organization (CDMO):</strong> Providing custom synthesis, process development, scale-up, and manufacturing services to pharmaceutical companies.</li>
<li><strong>Active Pharmaceutical Ingredients (APIs):</strong> Manufacturing and supplying APIs for various therapeutic areas.</li>
</ul>
<p><strong>Flagship or Signature Product Lines:</strong> The company specializes in niche APIs and advanced intermediates. Specific flagship products are often confidential due to client relationships.</p>
<p><strong>Key Technological Innovations or Patents:</strong> Suven focuses on developing innovative manufacturing processes for APIs and intermediates. The number of patents filed/granted would require further company-specific research.</p>
<p><strong>Manufacturing Facilities and Production Capacity:</strong> The company has multiple manufacturing facilities in India, equipped with advanced technology and infrastructure. Production capacity details are not readily available publicly and are competitively sensitive.</p>
<p><strong>Quality Certifications and Standards:</strong> Suven Pharmaceuticals adheres to stringent quality standards and holds certifications such as:</p>
<ul>
<li>US FDA</li>
<li>European GMP (Good Manufacturing Practice)</li>
<li>Other relevant regulatory approvals.</li>
</ul>
<p><strong>Any Unique Selling Propositions or Technological Advantages:</strong></p>
<ul>
<li><strong>Strong focus on niche APIs and intermediates:</strong> Allowing for high-value products.</li>
<li><strong>Integrated CDMO services:</strong> Providing end-to-end solutions to pharmaceutical clients.</li>
<li><strong>Strong R&amp;D capabilities:</strong> Enabling the development of innovative manufacturing processes.</li>
</ul>
<h3 class="heading" id="primary-customers">
  Primary Customers
  <a class="anchor" href="#primary-customers">#</a>
</h3>
<p><strong>Target Industries and Sectors:</strong> The primary target industry is the global pharmaceutical industry.</p>
<p><strong>Geographic Markets (domestic vs. international):</strong> Primarily international markets, including North America, Europe, and Asia.</p>
<p><strong>Major Client Segments:</strong> Pharmaceutical companies requiring CDMO services and APIs.</p>
<p><strong>Distribution Network and Sales Channels:</strong> Direct sales and marketing to pharmaceutical companies.</p>
<h3 class="heading" id="major-competitors">
  Major Competitors
  <a class="anchor" href="#major-competitors">#</a>
</h3>
<p><strong>Direct Competitors in India and Globally:</strong></p>
<ul>
<li><strong>In India:</strong> Divis Laboratories, Laurus Labs, Syngene International.</li>
<li><strong>Globally:</strong> Lonza, Catalent, Thermo Fisher Scientific (for CDMO services).</li>
</ul>
<p><strong>Competitive Advantages and Disadvantages:</strong></p>
<ul>
<li><strong>Advantages:</strong> Strong R&amp;D capabilities, focus on niche APIs, integrated CDMO services.</li>
<li><strong>Disadvantages:</strong> Subject to market volatility and regulatory changes, intense competition in the CDMO space.</li>
</ul>
<p><strong>How they differentiate from competitors:</strong> Focus on niche products, strong client relationships, and a commitment to quality and innovation.</p>
<h3 class="heading" id="future-outlook">
  Future Outlook
  <a class="anchor" href="#future-outlook">#</a>
</h3>
<p><strong>Expansion Plans or Growth Strategy:</strong> Suven Pharmaceuticals aims to expand its manufacturing capacity, strengthen its R&amp;D capabilities, and expand its geographic reach through organic growth and strategic acquisitions.</p>
<p><strong>Upcoming Products or Innovations:</strong> Focus on developing new APIs and innovative manufacturing processes.</p>
<p><strong>Sustainability Initiatives or ESG Commitments:</strong> Suven Pharmaceuticals is increasingly focusing on sustainability initiatives and ESG (Environmental, Social, and Governance) commitments. (Specific details on these commitments should be sought from the company&rsquo;s official communications.)</p>
<p><strong>Industry Trends Affecting their Business:</strong></p>
<ul>
<li><strong>Increasing demand for CDMO services:</strong> Driven by pharmaceutical companies focusing on core competencies.</li>
<li><strong>Growing demand for APIs:</strong> Driven by the growth of the pharmaceutical industry.</li>
<li><strong>Increasing regulatory scrutiny:</strong> Requiring companies to adhere to stringent quality standards.</li>
</ul>
<p><strong>Long-term Vision and Strategic Goals:</strong> To be a leading global CDMO and API supplier, providing innovative and high-quality solutions to the pharmaceutical industry.</p>
<hr>
<h2 class="heading" id="suven-pharmaceuticals-limited-financial-analysis">
  Suven Pharmaceuticals Limited: Financial Analysis
  <a class="anchor" href="#suven-pharmaceuticals-limited-financial-analysis">#</a>
</h2>
<h3 class="heading" id="3-year-trend-analysis-of-key-financial-metrics">
  3-Year Trend Analysis of Key Financial Metrics
  <a class="anchor" href="#3-year-trend-analysis-of-key-financial-metrics">#</a>
</h3>
<ul>
<li><strong>Revenue:</strong> Consolidated revenue decreased by 21.6% in FY24 (₹1,051.35 crore) compared to FY23 (₹1,340.33 crore), and adjusted for the COVID base and Agro chemical destocking cycle, the business grew at 16.2% in FY24. The Pharma segment, adjusted for the COVID base, grew at 9.4%.</li>
<li><strong>EBITDA:</strong> Consolidated EBITDA decreased from ₹587.6 crore in FY23 to ₹435 crore in FY24. Adjusted EBITDA margins for FY24 stood at 41.4% (43.8% in FY23), after one-time adjustments of ₹211 crore.</li>
<li><strong>Profitability:</strong> Consolidated Profit for the Year decreased from ₹411.29 crore in FY23 to ₹300.28 crore in FY24. The Adjusted PAT margin, was reported as 30.4%.</li>
<li><strong>Debt Equity Ratio:</strong> Improved to 0.02 in FY24 from 0.04 in FY23, due to decreased borrowings.</li>
<li><strong>Current Ratio:</strong> Increased to 11.47 in FY24 from 6.19 in FY23, due to increased investments and decreased current liabilities.</li>
<li><strong>Operating Profit Margin</strong>: decreased to 35.23% in FY24, compared to 40.62% due to decrese in revenue.</li>
</ul>
<h3 class="heading" id="business-segment-performance">
  Business Segment Performance
  <a class="anchor" href="#business-segment-performance">#</a>
</h3>
<ul>
<li><strong>Pharma CDMO:</strong> The Pharma segment adjusting for the COVID base, grew at 9.4%. The company is targeting to double the sales of its Pharma CDMO business over the next five years. The number of intermediates in Phase III increased from 6 to 13, and molecules in Phase III increased from 2 to 7. RFQs and conversions have more than doubled compared to previous years.</li>
<li><strong>Specialty Chemicals CDMO:</strong> Reframed as a new strategic business unit with increased investment in domain experts and infrastructure. The company anticipates trend reversal in growth from Q2 FY25.</li>
<li><strong>API++ (Cohance Lifesciences):</strong> Expects double digit growth through market share expansion and new product validations.</li>
</ul>
<h3 class="heading" id="major-strategic-initiatives-and-their-progress">
  Major Strategic Initiatives and Their Progress
  <a class="anchor" href="#major-strategic-initiatives-and-their-progress">#</a>
</h3>
<ul>
<li><strong>Customer Engagement:</strong> Increased customer engagement resulted in a significant increase in RFQs, with conversion rates more than doubling.</li>
<li><strong>Cost Optimization:</strong> Over 30 implementable cost-saving ideas from the shop/floor team, contributing to expense optimization.</li>
<li><strong>Infrastructure Upgrades:</strong> Completed an FDA audit with Zero 483 observations at the Pashamylaram facility. Inaugurated a new R&amp;D facility in Genome Valley. The new block in Suryapet is undergoing validations and is on track for commissioning.</li>
<li><strong>Merger with Cohance Lifesciences:</strong> The merger is progressing, with approvals received from NSE and BSE. The expected timeline for completion is 12-15 months from February 29, 2024. The merger is expected to accelerate growth momentum and expand capabilities.</li>
<li><strong>Acquisition of Sapala Organics Private Limited:</strong> pending statutory approvals, your company plans an initial acquisition of a 67.5% equity stake, which aims to boost the companies capabilities.</li>
</ul>
<h3 class="heading" id="risk-landscape-changes">
  Risk Landscape Changes
  <a class="anchor" href="#risk-landscape-changes">#</a>
</h3>
<ul>
<li><strong>Geopolitical Risks:</strong> Global players seeking to de-risk supply chains from China (China+1 strategy) present opportunities for Indian CDMOs. The USA&rsquo;s Biosecure Act potentially creates further opportunities.</li>
<li><strong>European Cost Pressures:</strong> High manufacturing costs in Europe are driving enterprises to shift their sourcing base towards Asia, particularly India.</li>
<li><strong>Dependence on Imports</strong>:Reliance on imports for KSM and APIs can affect delivery schedule.</li>
<li><strong>Client and Molecule Concentration</strong>: Reliance on select client and a limited number of key molecules.</li>
</ul>
<h3 class="heading" id="esg-initiatives-and-metrics">
  ESG Initiatives and Metrics
  <a class="anchor" href="#esg-initiatives-and-metrics">#</a>
</h3>
<ul>
<li><strong>EHS Awards:</strong> Pashamylaram Unit 3 received the EHS Excellence Award by the CII. The Pashamylaram facility also received the International Safety Award from the British Safety Council.</li>
<li><strong>CSR Spending:</strong> ₹778.12 lakhs spent on social and environmental commitments in 2023-24. Focus areas include education, healthcare, women empowerment, environmental sustainability, rural development, and safe drinking water.</li>
</ul>
<h3 class="heading" id="management-outlook">
  Management Outlook
  <a class="anchor" href="#management-outlook">#</a>
</h3>
<ul>
<li><strong>FY25 Outlook:</strong> Positive outlook for FY25, with expected growth in revenue and EBITDA, driven by an increase in the clinical pipeline and China Plus One dynamics. Recovery is expected in H2 FY25.</li>
<li><strong>Mid-Term to Long-Term Growth:</strong> The Company anticipates accelerated growth, supported by favourable industry conditions and increased inquiries for commercial molecules under patent.</li>
<li><strong>Cohance Merger impact</strong>: At a combined platform level, expected to organically double the business over the next /five years and adding further growth traction from M&amp;A opportunities.</li>
</ul>
<hr>
<h4 class="heading" id="detailed-analysis">
  Detailed Analysis
  <a class="anchor" href="#detailed-analysis">#</a>
</h4>
<hr>
<h2 class="heading" id="financial-position-analysis-of-suven-pharmaceuticals-limited">
  Financial Position Analysis of Suven Pharmaceuticals Limited
  <a class="anchor" href="#financial-position-analysis-of-suven-pharmaceuticals-limited">#</a>
</h2>
<h3 class="heading" id="balance-sheet---3-year-comparative-analysis-consolidated-in-c-lakhs">
  Balance Sheet - 3-Year Comparative Analysis (Consolidated, in C Lakhs)
  <a class="anchor" href="#balance-sheet---3-year-comparative-analysis-consolidated-in-c-lakhs">#</a>
</h3>
<table>
  <thead>
      <tr>
          <th style="text-align: left">Item</th>
          <th style="text-align: right">March 31, 2024</th>
          <th style="text-align: right">March 31, 2023</th>
          <th style="text-align: right">March 31, 2022</th>
      </tr>
  </thead>
  <tbody>
      <tr>
          <td style="text-align: left"><strong>Assets</strong></td>
          <td style="text-align: right"></td>
          <td style="text-align: right"></td>
          <td style="text-align: right"></td>
      </tr>
      <tr>
          <td style="text-align: left">Non-Current Assets</td>
          <td style="text-align: right">99,090.02</td>
          <td style="text-align: right">95,469.80</td>
          <td style="text-align: right">95,097.86</td>
      </tr>
      <tr>
          <td style="text-align: left">Current Assets</td>
          <td style="text-align: right">1,26,318.63</td>
          <td style="text-align: right">1,01,104.58</td>
          <td style="text-align: right">94,381.58</td>
      </tr>
      <tr>
          <td style="text-align: left"><strong>Total Assets</strong></td>
          <td style="text-align: right"><strong>2,25,408.65</strong></td>
          <td style="text-align: right"><strong>1,96,574.38</strong></td>
          <td style="text-align: right"><strong>1,89,479.44</strong></td>
      </tr>
      <tr>
          <td style="text-align: left"><strong>Equity</strong></td>
          <td style="text-align: right"></td>
          <td style="text-align: right"></td>
          <td style="text-align: right"></td>
      </tr>
      <tr>
          <td style="text-align: left">Equity Share Capital</td>
          <td style="text-align: right">2,545.65</td>
          <td style="text-align: right">2,545.65</td>
          <td style="text-align: right">2,545.65</td>
      </tr>
      <tr>
          <td style="text-align: left">Other Equity</td>
          <td style="text-align: right">2,02,520.70</td>
          <td style="text-align: right">1,70,972.78</td>
          <td style="text-align: right">1,47,626.74</td>
      </tr>
      <tr>
          <td style="text-align: left"><strong>Total Equity</strong></td>
          <td style="text-align: right"><strong>2,05,066.35</strong></td>
          <td style="text-align: right"><strong>1,73,518.43</strong></td>
          <td style="text-align: right"><strong>1,50,172.39</strong></td>
      </tr>
      <tr>
          <td style="text-align: left"><strong>Liabilities</strong></td>
          <td style="text-align: right"></td>
          <td style="text-align: right"></td>
          <td style="text-align: right"></td>
      </tr>
      <tr>
          <td style="text-align: left">Non-Current Liabilities</td>
          <td style="text-align: right">9,652.73</td>
          <td style="text-align: right">7,179.37</td>
          <td style="text-align: right">5,725.22</td>
      </tr>
      <tr>
          <td style="text-align: left">Current Liabilities</td>
          <td style="text-align: right">10,689.57</td>
          <td style="text-align: right">15,876.59</td>
          <td style="text-align: right">33,581.83</td>
      </tr>
      <tr>
          <td style="text-align: left"><strong>Total Liabilities</strong></td>
          <td style="text-align: right"><strong>20,342.30</strong></td>
          <td style="text-align: right"><strong>23,055.95</strong></td>
          <td style="text-align: right"><strong>39,307.05</strong></td>
      </tr>
  </tbody>
</table>
<h3 class="heading" id="significant-year-over-year-changes-10">
  Significant Year-over-Year Changes (&gt;10%)
  <a class="anchor" href="#significant-year-over-year-changes-10">#</a>
</h3>
<ul>
<li><strong>Current Assets (FY24 vs. FY23):</strong> Increased by 24.93%, primarily due to the increase of investment in mutual funds by 80%.</li>
<li><strong>Total Equity (FY24 vs. FY23):</strong> Increased by 18.18% which increased from retained earning.</li>
<li><strong>Current Liabilities (FY24 vs. FY23):</strong> Decreased by 32.67%, mainly because of the decrease of trade payable.</li>
</ul>
<h3 class="heading" id="working-capital-trends">
  Working Capital Trends
  <a class="anchor" href="#working-capital-trends">#</a>
</h3>
<table>
  <thead>
      <tr>
          <th>Metric</th>
          <th>March 31, 2024</th>
          <th>March 31, 2023</th>
      </tr>
  </thead>
  <tbody>
      <tr>
          <td>Current Assets</td>
          <td>1,26,318.63</td>
          <td>1,01,104.58</td>
      </tr>
      <tr>
          <td>Current Liabilities</td>
          <td>10,689.57</td>
          <td>15,876.59</td>
      </tr>
      <tr>
          <td>Working Capital</td>
          <td>1,15,629.06</td>
          <td>85,227.99</td>
      </tr>
      <tr>
          <td>Current Ratio</td>
          <td>11.82</td>
          <td>6.37</td>
      </tr>
  </tbody>
</table>
<p><em>Working capital increased significantly, driven by growth in current investments. The current ratio has drastically improved, indicating enhanced short-term solvency.</em></p>
<h3 class="heading" id="debt-structure-and-maturity-profile">
  Debt Structure and Maturity Profile
  <a class="anchor" href="#debt-structure-and-maturity-profile">#</a>
</h3>
<table>
  <thead>
      <tr>
          <th style="text-align: left">Debt Type</th>
          <th style="text-align: right">March 31, 2024</th>
          <th style="text-align: right">March 31, 2023</th>
      </tr>
  </thead>
  <tbody>
      <tr>
          <td style="text-align: left">Non-Current Borrowings</td>
          <td style="text-align: right">-</td>
          <td style="text-align: right">456.42</td>
      </tr>
      <tr>
          <td style="text-align: left">Current Borrowings (Short-term)</td>
          <td style="text-align: right">3,857.53</td>
          <td style="text-align: right">6,459.78</td>
      </tr>
      <tr>
          <td style="text-align: left">Lease Liabilities</td>
          <td style="text-align: right">2,642.11</td>
          <td style="text-align: right">117.88</td>
      </tr>
  </tbody>
</table>
<p><em>Current portion of long-term debt significantly reduced.</em></p>
<h3 class="heading" id="off-balance-sheet-items">
  Off-Balance Sheet Items
  <a class="anchor" href="#off-balance-sheet-items">#</a>
</h3>
<ul>
<li><strong>Contingent Liabilities:</strong> C 1,585.23 lakhs as of March 31, 2024, related to APIIC-JN Pharmacity restoration fees and disputes with indirect taxes.</li>
<li><strong>Commitments:</strong> C 4,044.73 committed for exectution of capital contracts.</li>
</ul>
<h2 class="heading" id="operating-performance-analysis-of-suven-pharmaceuticals-fy24">
  Operating Performance Analysis of Suven Pharmaceuticals (FY24)
  <a class="anchor" href="#operating-performance-analysis-of-suven-pharmaceuticals-fy24">#</a>
</h2>
<h3 class="heading" id="revenue-breakdown">
  Revenue Breakdown
  <a class="anchor" href="#revenue-breakdown">#</a>
</h3>
<ul>
<li>Consolidated Revenue (FY24 vs. FY23): Declined by 21.6% from ₹1,34,033 lakhs to ₹1,05,135 lakhs. The Pharma segment, adjusted for the COVID base, grew at 9.4%.</li>
<li>Standalone Revenue: Decreased by 23% from ₹1,33,008 Lakhs (FY23) to ₹1,02,499 Lakhs (FY24).</li>
<li>Exports: Constituted 89.79% of total revenue from operations, amounting to ₹92,034 lakhs in FY24.</li>
</ul>
<h4 class="heading" id="geographic-revenue-breakdown--in-lakhs">
  Geographic Revenue Breakdown (₹ in Lakhs)
  <a class="anchor" href="#geographic-revenue-breakdown--in-lakhs">#</a>
</h4>
<table>
  <thead>
      <tr>
          <th>Region</th>
          <th>FY24</th>
          <th>FY23</th>
      </tr>
  </thead>
  <tbody>
      <tr>
          <td>Europe</td>
          <td>73,622.83</td>
          <td>1,16,177.39</td>
      </tr>
      <tr>
          <td>North America</td>
          <td>15,025.86</td>
          <td>8,339.01</td>
      </tr>
      <tr>
          <td>India</td>
          <td>9,392.17</td>
          <td>2,593.35</td>
      </tr>
      <tr>
          <td>Rest of World</td>
          <td>5,543.79</td>
          <td>6,001.26</td>
      </tr>
      <tr>
          <td>Related Party</td>
          <td>492.93</td>
          <td>614.27</td>
      </tr>
  </tbody>
</table>
<h3 class="heading" id="cost-structure-analysis-standalone">
  Cost Structure Analysis (Standalone)
  <a class="anchor" href="#cost-structure-analysis-standalone">#</a>
</h3>
<ul>
<li>Cost of Materials Consumed: Decreased from ₹42,136.24 lakhs (FY23) to ₹24,838.44 lakhs (FY24).</li>
<li>Employee Benefit Expenses: Increased from ₹10,858.10 lakhs (FY23) to ₹12,687.84 lakhs (FY24).</li>
<li>Manufacturing expenses: Decreased from ₹17,164.59(FY23) to ₹12,777.79 (FY24).</li>
</ul>
<h3 class="heading" id="margin-analysis-consolidated">
  Margin Analysis (Consolidated)
  <a class="anchor" href="#margin-analysis-consolidated">#</a>
</h3>
<ul>
<li>Reported EBITDA Margin (FY24): 39.4%.</li>
<li>Adjusted EBITDA Margin (FY24): 41.4% (adjusting for one-time costs of ₹769 lakhs, including ESOP charge and expenses for the proposed merger).</li>
<li>Adjusted EBITDA Margins (FY23): 43.8%.</li>
<li>Adjusted PAT Margin (FY24): 30.4%.</li>
</ul>
<h4 class="heading" id="standalone-margin-analysis">
  Standalone Margin Analysis
  <a class="anchor" href="#standalone-margin-analysis">#</a>
</h4>
<ul>
<li>Operating Profit Margin: 35.23% (FY24) vs. 40.62% (FY23)</li>
<li>Net Profit Margin: 28% (FY24) vs. 33% (FY23)</li>
</ul>
<h3 class="heading" id="non-recurring-items-consolidated">
  Non-Recurring Items (Consolidated)
  <a class="anchor" href="#non-recurring-items-consolidated">#</a>
</h3>
<ul>
<li>FY24 One-Time Costs: ₹769 lakhs, comprising an ESOP charge of ₹199 lakhs and ₹570 lakhs related to the proposed merger of Cohance Lifesciences.</li>
</ul>
<h3 class="heading" id="gaap-vs-non-gaap-reconciliation">
  GAAP vs. Non-GAAP Reconciliation
  <a class="anchor" href="#gaap-vs-non-gaap-reconciliation">#</a>
</h3>
<ul>
<li>Adjusted EBITDA provided with exclusion for one-time costs.</li>
</ul>
<h3 class="heading" id="eps-analysis-consolidated">
  EPS Analysis (Consolidated)
  <a class="anchor" href="#eps-analysis-consolidated">#</a>
</h3>
<ul>
<li>Basic EPS: Decreased from ₹16.16 (FY23) to ₹11.80 (FY24).</li>
<li>Diluted EPS: Decreased from ₹16.16 (FY23) to ₹11.80 (FY24).</li>
</ul>
<h2 class="heading" id="cash-management-suven-pharmaceuticals-financial-analysis">
  Cash Management: Suven Pharmaceuticals Financial Analysis
  <a class="anchor" href="#cash-management-suven-pharmaceuticals-financial-analysis">#</a>
</h2>
<h3 class="heading" id="cash-flow-and-liquidity-analysis">
  Cash Flow and Liquidity Analysis
  <a class="anchor" href="#cash-flow-and-liquidity-analysis">#</a>
</h3>
<h4 class="heading" id="ocf-icf-components-consolidated">
  OCF, ICF Components (Consolidated)
  <a class="anchor" href="#ocf-icf-components-consolidated">#</a>
</h4>
<ul>
<li><strong>OCF:</strong> FY24: ₹358.48 crore, down from ₹492.82 crore in FY23. Decrease driven by lower profit before tax. Operating profit before working capital changes was ₹413.12 crore, down from ₹572.54 crore.</li>
<li><strong>ICF:</strong> FY24: ₹(362.25) crore, decreased from ₹(195.01) crore in FY23. Driven by purchase of property, plant and equipment and sale/(purchase) of mutual funds.</li>
</ul>
<h4 class="heading" id="working-capital-management-efficiency-consolidated">
  Working Capital Management Efficiency (Consolidated)
  <a class="anchor" href="#working-capital-management-efficiency-consolidated">#</a>
</h4>
<ul>
<li>Inventory turnover days: 74 in FY24 vs 86 in FY23.</li>
<li>Debtor turnover days: 43 in FY24 vs 30 in FY23.</li>
</ul>
<h4 class="heading" id="capex-analysis">
  Capex Analysis
  <a class="anchor" href="#capex-analysis">#</a>
</h4>
<ul>
<li>Total Property, Plant and Equipment additions (capitalized) during FY24 were ₹7,765.36 lakhs (Standalone) and ₹8,276.06 lakhs (Consolidated).</li>
</ul>
<h4 class="heading" id="dividend-and-share-buyback-trends">
  Dividend and Share Buyback Trends
  <a class="anchor" href="#dividend-and-share-buyback-trends">#</a>
</h4>
<ul>
<li>No dividends paid or proposed in FY24. Previous period dividend was ₹203.65 crore.</li>
<li>No share buyback information available.</li>
</ul>
<h4 class="heading" id="debt-service-coverage-consolidated">
  Debt Service Coverage (Consolidated)
  <a class="anchor" href="#debt-service-coverage-consolidated">#</a>
</h4>
<ul>
<li>Debt Service Coverage Ratio: 8.67 in FY24, down from 12.05 in FY23.</li>
<li>Interest Coverage Ratio: 62.61 times in FY24, up from 49.83 in FY23 due to decreased borrowing costs.</li>
</ul>
<h4 class="heading" id="liquidity-position-consolidated">
  Liquidity Position (Consolidated)
  <a class="anchor" href="#liquidity-position-consolidated">#</a>
</h4>
<ul>
<li>Current Ratio: 11.47 in FY24, increased from 6.19 in FY23.</li>
</ul>
<h2 class="heading" id="financial-analysis-key-performance-indicators">
  Financial Analysis: Key Performance Indicators
  <a class="anchor" href="#financial-analysis-key-performance-indicators">#</a>
</h2>
<h3 class="heading" id="profitability-ratios-3-year-trends">
  Profitability Ratios (3-Year Trends)
  <a class="anchor" href="#profitability-ratios-3-year-trends">#</a>
</h3>
<ul>
<li><strong>Return on Equity (ROE):</strong> FY24: 16%, FY23: 26%. A significant decrease is observed, indicating reduced profitability relative to shareholders&rsquo; equity.</li>
<li><strong>Operating Profit Margin:</strong> FY24: 35.23%, FY23: 40.62%. The operating margin decreased, indicating lower profitability.</li>
<li><strong>Net Profit Margin:</strong> FY24: 28% , FY23: 33%. The net profit margin has decreased, suggesting reduced efficiency in converting revenue to profit.</li>
</ul>
<h3 class="heading" id="liquidity-metrics">
  Liquidity Metrics
  <a class="anchor" href="#liquidity-metrics">#</a>
</h3>
<ul>
<li><strong>Current Ratio:</strong> FY24: 11.47, FY23: 6.19. The Group&rsquo;s current ratio is very high and increased substantially, indicating strong short-term solvency, far exceeding standard benchmarks.</li>
</ul>
<h3 class="heading" id="efficiency-ratios">
  Efficiency Ratios
  <a class="anchor" href="#efficiency-ratios">#</a>
</h3>
<ul>
<li><strong>Inventory Turnover Ratio (Days):</strong> FY24: 74 days, FY23: 86 days. Inventory turnover improved in FY24, requiring fewer days to convert, but it still suggest slow moving.</li>
<li><strong>Debtor Turnover Ratio (Days):</strong> FY24: 43 days, FY23: 30 days. The debtor turnover period increased, indicating slower collection from customers.</li>
</ul>
<h3 class="heading" id="leverage-metrics">
  Leverage Metrics
  <a class="anchor" href="#leverage-metrics">#</a>
</h3>
<ul>
<li><strong>Debt-Equity Ratio:</strong> FY24: 0.02, FY23: 0.04. The Group has very low leverage, with minimal debt compared to equity and improved slightly.</li>
<li><strong>Interest Coverage Ratio:</strong> FY24: 62.61, FY23: 49.83. The very high-interest coverage ratio improved, demonstrating the Group&rsquo;s strong ability to meet interest obligations, exceeding the industry by large numbers.</li>
</ul>
<h3 class="heading" id="working-capital-ratios">
  Working Capital Ratios
  <a class="anchor" href="#working-capital-ratios">#</a>
</h3>
<ul>
<li><strong>Working Capital Ratio:</strong> The working capital of the Group has seen a decrease when revenue and profitability are decreasing.</li>
</ul>
<h3 class="heading" id="comparison-with-industry-averages-and-significant-deviations">
  Comparison with Industry Averages and Significant Deviations
  <a class="anchor" href="#comparison-with-industry-averages-and-significant-deviations">#</a>
</h3>
<ul>
<li><strong>Profitability:</strong> The decrease in profitability ratios (ROE, and Profit margins) is significant despite still holding high numbers.</li>
<li><strong>Liquidity:</strong> The extremely high current ratio suggests a potential over-investment in current assets or under-utilization of available capital.</li>
<li><strong>Efficiency:</strong> The increase in debtor turnover days needs to be addressed.</li>
<li><strong>Leverage:</strong> Very low debt/equity ratio indicates the Group is financing its operations largely through equity.</li>
<li>The company generated a postive cash flow from operations for the FY24.</li>
</ul>
<h2 class="heading" id="suven-pharmaceuticals-limited-financial-analysis-fy24">
  Suven Pharmaceuticals Limited: Financial Analysis (FY24)
  <a class="anchor" href="#suven-pharmaceuticals-limited-financial-analysis-fy24">#</a>
</h2>
<h3 class="heading" id="segment-performance-analysis">
  Segment Performance Analysis
  <a class="anchor" href="#segment-performance-analysis">#</a>
</h3>
<h4 class="heading" id="revenue-and-profitability-metrics-with-growth-rates">
  Revenue and Profitability Metrics with Growth Rates
  <a class="anchor" href="#revenue-and-profitability-metrics-with-growth-rates">#</a>
</h4>
<ul>
<li>Overall Revenue: Declined by 21.6% (Consolidated, FY24 vs. FY23), from ₹1,340.33 crore to ₹1,051.35 crore. Standalone revenue decreased by 23%.</li>
<li>Pharma CDMO (ex-COVID base): Grew by 9.4% in FY24.</li>
<li>Adjusting for COVID base and Agro Chemical destocking cycle: the business grew by 16.2% on a consolidated Basis in FY24.</li>
<li>EBITDA: Decreased from ₹587.6 crore (FY23) to ₹435 crore (FY24) on a consolidated basis.</li>
<li>Reported EBITDA Margin (Consolidated): 39.4% (FY24), a decrease from the previous year.</li>
<li>Adjusted EBITDA Margin (Consolidated, excluding one-time costs): 41.4% (FY24), was stated as 43.8% for FY23.</li>
<li>Profit for the Year (Consolidated): Decreased from ₹411.29 crore (FY23) to ₹300.28 crore (FY24).</li>
<li>Net Profit Margin: Slipped to 28% compared to 33% the previous year.</li>
</ul>
<h4 class="heading" id="market-share-and-competitive-position">
  Market Share and Competitive Position
  <a class="anchor" href="#market-share-and-competitive-position">#</a>
</h4>
<ul>
<li>The company aims to become a Tier-1 supplier to its top 5 customers.</li>
<li>The Company is growing its customer base and served more than 30 innovator companies in the last 5 years.</li>
</ul>
<h4 class="heading" id="key-productsservices-performance">
  Key Products/Services Performance
  <a class="anchor" href="#key-productsservices-performance">#</a>
</h4>
<ul>
<li><strong>Pharma CDMO:</strong> Witnessed a significant increase in RFQs, with conversions more than doubling compared to previous years. Phase III intermediates increased from 6 to 13, and Phase III molecules increased from 2 to 7 (FY23 vs. FY24).</li>
<li><strong>Specialty Chemicals CDMO:</strong> Remodeled as a new strategic business unit.</li>
<li><strong>Cohance Lifesciences (Merger Target):</strong> ADC platform is growing significantly; Non-ADC CDMO has one product progressing well in Phase 3; API plus business is expected to return to healthy growth rates. 5 new product validations by Cohance were completed by March 2024.</li>
</ul>
<h4 class="heading" id="geographic-distribution-and-market-penetration">
  Geographic Distribution and Market Penetration
  <a class="anchor" href="#geographic-distribution-and-market-penetration">#</a>
</h4>
<ul>
<li>Exports: Accounted for 89.79% of total revenue from operations (₹92,034 lakhs out of ₹1,02,499 lakhs) in FY24.</li>
<li>Key Markets: USA and Europe are the largest markets, while Asia Pacific is the second largest.</li>
<li>The company has a physical presence and operations in: India (multiple locations), and the USA (New Jersey).</li>
</ul>
<h4 class="heading" id="segment-wise-capex-and-roic">
  Segment-wise CAPEX and ROIC
  <a class="anchor" href="#segment-wise-capex-and-roic">#</a>
</h4>
<ul>
<li>New R&amp;D Facility: The company has set up a new 25,000 Sq.Ft R&amp;D Facility.</li>
<li>R&amp;D expenditure: It increased from Rs. 8.59 Crores to 16.12 Crore.</li>
</ul>
<h4 class="heading" id="operational-efficiency-metrics">
  Operational Efficiency Metrics
  <a class="anchor" href="#operational-efficiency-metrics">#</a>
</h4>
<ul>
<li>Cost Optimization: Over 30 implementable cost-saving ideas generated from the shop floor team.</li>
<li>Inventory Turnover Ratio: at 74 days from 86 days.</li>
<li>Debtor Turnover Ratio: Increased to 43 days, decreased from 30 days, indicating a slower collection cycle.</li>
</ul>
<h4 class="heading" id="growth-initiatives-and-challenges">
  Growth Initiatives and Challenges
  <a class="anchor" href="#growth-initiatives-and-challenges">#</a>
</h4>
<ul>
<li><strong>Growth Initiatives:</strong>
<ul>
<li>Scaling and deepening existing customer relationships, aiming to become a Tier-1 supplier.</li>
<li>Scaling up developmental revenues and investing in infrastructure.</li>
<li>Moving up the value chain from intermediates to API levels.</li>
<li>Building a winning lateral business by farming existing customers.</li>
<li>Incubating/acquiring select new technologies (e.g., flow chemistry, oligonucleotides).</li>
<li>Merger with Cohance Lifesciences to expand capabilities and accelerate growth.</li>
<li>Acquiring Sapala Organics to expand technological capabilities.</li>
</ul>
</li>
<li><strong>Challenges:</strong>
<ul>
<li>Reliance on imports for Key Starting Materials (KSM) and APIs.</li>
<li>A significant portion of the business relies on a select clientele and a limited number of key molecules.</li>
<li>Price competition from generic players.</li>
<li>Reliance on innovator molecules progressing to subsequent phases of clinical development.</li>
<li>FY24 was impacted by a global slowdown, Agro-Chemical destocking, COVID base effect, and commodity pricing.</li>
</ul>
</li>
</ul>
<h2 class="heading" id="suven-pharmaceuticals-limited---segment-wise-risk-analysis-fy2023-24-vs-fy2022-23">
  Suven Pharmaceuticals Limited - Segment-Wise Risk Analysis (FY2023-24 vs. FY2022-23)
  <a class="anchor" href="#suven-pharmaceuticals-limited---segment-wise-risk-analysis-fy2023-24-vs-fy2022-23">#</a>
</h2>
<p>The provided document combined all operations into a single reportable segment that manufactures NCE-based intermediates, API&rsquo;s, specialty chemicals and formulations.</p>
<h2 class="heading" id="strategic-risks">
  Strategic Risks
  <a class="anchor" href="#strategic-risks">#</a>
</h2>
<ul>
<li><strong>Severity:</strong> High. Reliance on innovator molecules progressing to subsequent phases of clinical development and reliance on key clients are sources for material revenue loss.</li>
<li><strong>Likelihood:</strong> Medium. The pharmaceutical industry faces challenges, including late-stage asset failures.</li>
<li><strong>Trend:</strong> Increasing. The clinical pipeline growth and China Plus One dynamics are increasing RFQs, potentially exacerbating reliance on key clients and molecules. Phase III intermediates increased from 6 to 13, and molecules from 2 to 7.</li>
<li><strong>Mitigation Strategies:</strong> Scale and deepen existing relationships, scale up developmental revenues, move up the value chain. Build and deploy key account management.</li>
<li><strong>Control Effectiveness:</strong> Partially Effective. Increase in RFQs and conversion rates indicate some success, yet the core risks remain.</li>
<li><strong>Potential Financial Impact:</strong> Significant revenue decline if key molecules fail or key customer relationships are impacted. FY24 saw a revenue decline of 21.6% (Consolidated).</li>
</ul>
<h2 class="heading" id="operational-risks">
  Operational Risks
  <a class="anchor" href="#operational-risks">#</a>
</h2>
<ul>
<li><strong>Severity:</strong> Medium to High. Reliance on imports for Key Starting Materials (KSM) and Active Pharmaceutical Ingredients (APIs).</li>
<li><strong>Likelihood:</strong> Medium. Supply chain disruptions are mentioned as an industry headwind.</li>
<li><strong>Trend:</strong> Stable. The company recognizes the risk.</li>
<li><strong>Mitigation Strategies:</strong> Cost optimization strategies, supplier risk mitigation, and minimizing China dependence. Implemented 30+ cost-saving ideas.</li>
<li><strong>Control Effectiveness:</strong> Partially effective. Cost-saving measures and FDA audit clearances indicate operational controls, but import reliance remains.</li>
<li><strong>Potential Financial Impact:</strong> Delivery schedule delays.</li>
</ul>
<h2 class="heading" id="financial-risks">
  Financial Risks
  <a class="anchor" href="#financial-risks">#</a>
</h2>
<ul>
<li><strong>Severity:</strong> Medium to High.</li>
<li><strong>Likelihood:</strong> Medium. Fluctuations in revenue and profitability.</li>
<li><strong>Trend:</strong> Increasing. The company reported a decrease in EBITDA (from C 587.6 crore in FY23 to C 435 crore in FY24) and Profit for the Year (from C 411.29 crore to C 300.28 crore).</li>
<li><strong>Mitigation Strategies:</strong> Cost optimization and supplier risk mitigation.</li>
<li><strong>Control Effectiveness:</strong> Partially effective. EBITDA margins are being maintained, but overall profitability has decreased.</li>
<li><strong>Potential Financial Impact:</strong>
<ul>
<li>Debt Service Coverage Ratio decreased by 28%.</li>
<li>Debtor Turnover Ratio (days) increased by 42%.</li>
<li>Operating Profit Margin (%) decreased by 13%.</li>
<li>Net Profit Margin (%) decreased by 14%.</li>
</ul>
</li>
</ul>
<h2 class="heading" id="complianceregulatory-risks">
  Compliance/Regulatory Risks
  <a class="anchor" href="#complianceregulatory-risks">#</a>
</h2>
<ul>
<li><strong>Severity:</strong> High. Any non-compliance with regulations could result in penalties and reputational damage.</li>
<li><strong>Likelihood:</strong> Low. The Company achieved USFDA audit clearance with Zero 483 observations, indicating strong compliance.</li>
<li><strong>Trend:</strong> Stable.</li>
<li><strong>Mitigation Strategies:</strong> Maintained EHS management and quality management systems.</li>
<li><strong>Control Effectiveness:</strong> High, as evidenced by successful audit outcomes.</li>
<li><strong>Potential Financial Impact:</strong> Not quantifiable from the provided data, but regulatory failures typically result in /fines and operational restrictions.</li>
</ul>
<h2 class="heading" id="emerging-risks">
  Emerging Risks
  <a class="anchor" href="#emerging-risks">#</a>
</h2>
<h3 class="heading" id="geopolitical-risks">
  Geopolitical Risks
  <a class="anchor" href="#geopolitical-risks">#</a>
</h3>
<ul>
<li>Severity: Medium to High.</li>
<li>Likelihood: Increasing. Geopolitical instability and supply chain issues were mentioned.</li>
<li>Trend: Increasing. The document mentions the USA&rsquo;s Biosecure Act impacting Chinese biotechnology firms, creating both opportunities and risks for Indian CDMOs.</li>
<li>Mitigation Strategies: Diversifying supply chains (China +1 strategy).</li>
<li>Control Effectiveness: The documents do not provide enough information to judge.</li>
<li>Potential Financial Impact: Not quantifiable, but potential supply chain disruptions and increased costs.</li>
</ul>
<h3 class="heading" id="agrochemical-sector-risks">
  Agrochemical Sector Risks
  <a class="anchor" href="#agrochemical-sector-risks">#</a>
</h3>
<ul>
<li>Severity: Medium to high.</li>
<li>Likelihood: Medium.</li>
<li>Trend: Unclear</li>
<li>Mitigation Strategies: The documents show a new strategic unit for specialty chemical.</li>
<li>Control Effectiveness: Not accessed in the documents.</li>
<li>Potential Financial Impact: 10-12% price decline and 5-7% volume decline in 2023.</li>
</ul>
<h2 class="heading" id="strategic-and-management-analysis-of-suven-pharmaceuticals">
  Strategic and Management Analysis of Suven Pharmaceuticals
  <a class="anchor" href="#strategic-and-management-analysis-of-suven-pharmaceuticals">#</a>
</h2>
<h3 class="heading" id="long-term-strategic-goals-and-progress">
  Long-Term Strategic Goals and Progress
  <a class="anchor" href="#long-term-strategic-goals-and-progress">#</a>
</h3>
<ul>
<li><strong>Goal:</strong> To double the sales of its Pharma CDMO business over the next five years while maintaining industry-leading EBITDA margins.</li>
<li><strong>Goal:</strong> To become India&rsquo;s most admired CDMO company by 2029.</li>
<li><strong>Progress:</strong> Operational progress in FY24 with enhanced customer engagement, including a 25% increase in RFQs, a higher win rate, and positive discussions with major innovator companies.</li>
<li><strong>Progress:</strong> Pipeline movement to Phase 3, doubled from 2 molecules to 7 molecules.</li>
<li><strong>Goal:</strong> Build or acquire new technology in areas including flow chemistry and oligonucleotides.</li>
<li><strong>Progress:</strong> Scouting for technology platforms, referencing Sapala Organics as a target.</li>
</ul>
<h3 class="heading" id="competitive-advantages-and-market-positioning">
  Competitive Advantages and Market Positioning
  <a class="anchor" href="#competitive-advantages-and-market-positioning">#</a>
</h3>
<ul>
<li><strong>Advantage:</strong> Pure-play CDMO, focusing on custom synthesis, process R&amp;D, scale-up, and contract manufacturing.</li>
<li><strong>Advantage:</strong> Possesses a large repository of chemistry skills, specializing in cyanation, heterocyclic, carbohydrate, and chiral chemistry.</li>
<li><strong>Advantage:</strong> Experience working with top global innovator companies.</li>
<li><strong>Advantage:</strong> Demonstrated on-time delivery track record (over 900 CDMO projects).</li>
<li><strong>Positioning:</strong> Shifting from a domestic CDMO player to a global CDMO partner-of-choice.</li>
<li><strong>Market Positioning:</strong> Plans to capitalize on favorable trends in the Indian CDMO space, such as the &ldquo;China Plus One&rdquo; strategy.</li>
</ul>
<h3 class="heading" id="innovation-initiatives-and-rd-effectiveness">
  Innovation Initiatives and R&amp;D Effectiveness
  <a class="anchor" href="#innovation-initiatives-and-rd-effectiveness">#</a>
</h3>
<ul>
<li><strong>Initiative:</strong> Modernization of R&amp;D facility, with a new campus at Genome Valley.</li>
<li><strong>Initiative:</strong> Prioritizes chemistry capabilities and niche chemistry.</li>
<li><strong>Effectiveness:</strong> Faster turnaround of RFQs due to digitalization.</li>
<li><strong>Effectiveness:</strong> Strengthening of process safety and Engineering division.</li>
<li><strong>R&amp;D Spend:</strong> FY24: ₹1,612 lakhs (1.57% of total turnover), up from ₹859 lakhs (0.6% of total turnover) in FY23.</li>
</ul>
<h3 class="heading" id="ma-strategy-and-execution">
  M&amp;A Strategy and Execution
  <a class="anchor" href="#ma-strategy-and-execution">#</a>
</h3>
<ul>
<li><strong>Strategy:</strong> Merger with Cohance Lifesciences to expand capabilities and market reach.</li>
<li><strong>Progress:</strong> Merger with Cohance Lifesciences is in progress, awaiting SEBI and NCLT approvals (expected timeline 12-15 months from February 29, 2024).</li>
<li><strong>Strategy:</strong> Plan to acquire Sapala Organics.</li>
<li><strong>Execution:</strong> Expanding via M&amp;A and is making progress with regulatory approval.</li>
</ul>
<h3 class="heading" id="managements-track-record-in-execution">
  Management&rsquo;s Track Record in Execution
  <a class="anchor" href="#managements-track-record-in-execution">#</a>
</h3>
<ul>
<li><strong>Execution:</strong> Successfully cleared USFDA audit with zero observations for the Pashamylaram facility.</li>
<li><strong>Execution:</strong> Implemented cost optimization initiatives.</li>
<li><strong>Execution:</strong> New management appointed with new strategies.</li>
<li><strong>Execution:</strong> Inaugurated state-of-the-art R&amp;D Facility.</li>
<li><strong>Execution:</strong> Change in management control pursuant to SEBI SAST Regulations.</li>
</ul>
<h3 class="heading" id="capital-allocation-strategy">
  Capital Allocation Strategy
  <a class="anchor" href="#capital-allocation-strategy">#</a>
</h3>
<ul>
<li><strong>Strategy:</strong> The company retained the entire profit for FY23-24 in retained earnings, and the Board does not recommend paying a dividend.</li>
<li><strong>Strategy:</strong> Focus on CAPEX, evidenced by the completion of an FDA audit and other regulatory audits at the Pashamylaram facility, as well as the inauguration of a new R&amp;D facility.</li>
<li><strong>Strategy:</strong> Investment in working capital as inventory turnover days has been reduced.</li>
<li><strong>Strategy:</strong> Reduction of debt, shown by a decrease in the debt-to-equity ratio.</li>
</ul>
<h3 class="heading" id="organizational-changes-and-their-impact">
  Organizational Changes and Their Impact
  <a class="anchor" href="#organizational-changes-and-their-impact">#</a>
</h3>
<ul>
<li><strong>Change:</strong> The founder promoters sold a 50.10% stake to Berhyanda Limited (Advent International) on September 29, 2023, resulting in a change of management control.</li>
<li><strong>Change:</strong> Significant turnover in Board of Directors and Key Managerial Personnel.</li>
<li><strong>Impact:</strong> Reconstitution of board committees. New management is implementing a new strategic roadmap, focusing on customer engagement, cost optimization, and infrastructure upgrades.</li>
<li><strong>Change:</strong> Creation of new Strategic Business Unit for Specialty Chemicals CDMO.</li>
<li><strong>Impact:</strong> Aim is to better allign with customer expectations and business needs.</li>
</ul>
<h2 class="heading" id="esg-framework">
  ESG Framework
  <a class="anchor" href="#esg-framework">#</a>
</h2>
<h3 class="heading" id="environmental-metrics-and-targets">
  Environmental Metrics and Targets
  <a class="anchor" href="#environmental-metrics-and-targets">#</a>
</h3>
<ul>
<li>Implemented energy conservation measures (auto On/Off switches for cooling towers, flash steam recovery system, LED lighting). Invested approximately ₹ 1 Crore.</li>
<li>Utilizing alternate energy sources: 3.05 MWp solar plant and biomass co-firing trials.</li>
<li>Pashamylaram Unit 3 site awarded the EHS Excellence Award by the CII.</li>
<li>Pashamylaram facility received the International Safety Award from the British Safety Council.</li>
</ul>
<h3 class="heading" id="social-responsibility-programs">
  Social Responsibility Programs
  <a class="anchor" href="#social-responsibility-programs">#</a>
</h3>
<ul>
<li>Spent ₹ 778.12 lakhs on social and environmental commitments in 2023-24.</li>
<li>Key CSR areas: education, healthcare, women empowerment, environmental sustainability, rural development, safe drinking water, and mid-day meal programs.</li>
<li>Supported education with books, uniforms, and fee assistance for underprivileged students, partnering for programs like &lsquo;Science on Wheels.&rsquo;</li>
<li>Contributed to the Roti Foundation for hunger management by donating over 37,500 meals, benefiting over 3,000 beneficiaries.</li>
<li>Setup drinking water facilities in various villages.</li>
</ul>
<h3 class="heading" id="governance-structure-and-effectiveness">
  Governance Structure and Effectiveness
  <a class="anchor" href="#governance-structure-and-effectiveness">#</a>
</h3>
<ul>
<li>Board of Directors: 50% Independent Directors, including one Woman Independent Director.</li>
<li>Board committees: Audit, Nomination and Remuneration, Stakeholders&rsquo; Relationship, Risk Management, and Corporate Social Responsibility (all committees have new members effective 29th September 2023).</li>
<li>Audit Committee composed of independent and non-executive directors.</li>
<li>Whistle Blower Policy in place.</li>
<li>Performance evaluation of the Board, its committees, and individual directors conducted as per the Companies Act, 2013 and SEBI (LODR) Regulations, 2015.</li>
</ul>
<h3 class="heading" id="regulatory-compliance-and-future-preparations">
  Regulatory Compliance and Future Preparations
  <a class="anchor" href="#regulatory-compliance-and-future-preparations">#</a>
</h3>
<ul>
<li>Pashamylaram facility cleared a USFDA audit with zero 483 observations; New block in Suryapet undergoing validations.</li>
<li>Maintains internal financial controls and has a risk management framework.</li>
<li>Complies with provisions related to the Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. No cases reported during the year.</li>
<li>Maintaining Cost Records as prescribed under the law.</li>
<li>Ensuring compliance of downstream investments in accordance with the Foreign Exchange Management (Non-debt Instruments) Rules,2019.</li>
</ul>



<div class="button-container">    
    <a href="https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fec80c4b-d2f3-496a-9e3b-d263ba26c9f7.pdf" target="_blank" class="report-button">
      <i class="fas fa-file-pdf"></i> Download Annual Report
    </a>
</div>
    



    
  </div>

  


  

  
  

<div class="single-pagination">
    <hr />

    <div class="flex">

        <div class="single-pagination-prev">
            
            <div class="single-pagination-container-prev">
                <div class="single-pagination-text">←</div>
                <div class="single-pagination-text">
                    <a href="/posts/linde-india-ltdannual-report-2023-24-analysis/">
                        Linde India Ltd:Annual Report 2023-24 Analysis
                    </a>
                </div>
            </div>
            
        </div>

        <div class="single-pagination-next">
            
            <div class="single-pagination-container-next">
                <div class="single-pagination-text">
                    <a href="/posts/coromandel-international-ltdannual-report-2023-24-analysis/">
                        Coromandel International Ltd:Annual Report 2023-24 Analysis
                    </a>
                </div>
                <div class="single-pagination-text">→</div>
            </div>
            
        </div>

    </div>

    <hr />
</div>



  <div id="disqus_thread"></div>
<script>
    

    

    (function() { 
    var d = document, s = d.createElement('script');
    s.src = 'https://muthuai.disqus.com/embed.js';
    s.setAttribute('data-timestamp', +new Date());
    (d.head || d.body).appendChild(s);
    })();
</script>
<noscript>Please enable JavaScript to view the <a href="https://disqus.com/?ref_noscript">comments powered by Disqus.</a></noscript>
  

  

  
  <div class="back-to-top">
    <a href="#top">
      back to top
    </a>
  </div>
  

</div>


    </main>
  </div>

  <footer>
    

    
    
    
    <p>Made with ♥ in India</p>
    


  </footer>

  

</body>

<script>

  function isAuto() {
    return document.body.classList.contains("auto");
  }

  function setTheme() {
    if (!isAuto()) {
      return
    }

    document.body.classList.remove("auto");
    let cls = "light";
    if (window.matchMedia && window.matchMedia('(prefers-color-scheme: dark)').matches) {
      cls = "dark";
    }

    document.body.classList.add(cls);
  }

  function invertBody() {
    document.body.classList.toggle("dark");
    document.body.classList.toggle("light");
  }

  if (isAuto()) {
    window.matchMedia('(prefers-color-scheme: dark)').addListener(invertBody);
  }

  setTheme();

</script>
<script>
    window.addEventListener('DOMContentLoaded', (event) => {
        new PagefindUI({ element: "#search", showSubResults: false, showImages: false });
    });
</script>
<script defer src="/js/copy-code.js"></script>
</html>